BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Möckel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev 2021;20:102736. [PMID: 33333233 DOI: 10.1016/j.autrev.2020.102736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu S, Miao JJ, Zhou X, Sun Q, Mao XM. High levels of thyroid hormones promote recurrence of Graves' disease via overexpression of B-cell-activating factor. J Clin Lab Anal 2022;:e24701. [PMID: 36097969 DOI: 10.1002/jcla.24701] [Reference Citation Analysis]
2 Kirou KA, Dall`era M, Aranow C, Anders H. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol 2022;13:980079. [DOI: 10.3389/fimmu.2022.980079] [Reference Citation Analysis]
3 Samões B, Zen M, Abelha-Aleixo J, Gatto M, Doria A. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus. Autoimmun Rev 2022;21:103165. [PMID: 35931316 DOI: 10.1016/j.autrev.2022.103165] [Reference Citation Analysis]
4 Grange L, Chalayer E, Boutboul D, Paul S, Galicier L, Gramont B, Killian M. TAFRO syndrome: A severe manifestation of Sjogren's syndrome? A systematic review. Autoimmun Rev 2022;21:103137. [PMID: 35803499 DOI: 10.1016/j.autrev.2022.103137] [Reference Citation Analysis]
5 Cheng H, Zhang X, Yang H, Yu Z, Yan C, Gao C, Wen H. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol 2022;13:911730. [DOI: 10.3389/fimmu.2022.911730] [Reference Citation Analysis]
6 Alturaiki W. Considerations for Novel COVID-19 Mucosal Vaccine Development. Vaccines (Basel) 2022;10:1173. [PMID: 35893822 DOI: 10.3390/vaccines10081173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wang W, Fan Y, Wang X. Lactobacillus: Friend or Foe for Systemic Lupus Erythematosus? Front Immunol 2022;13:883747. [PMID: 35677055 DOI: 10.3389/fimmu.2022.883747] [Reference Citation Analysis]
8 Mubariki R, Vadasz Z. The role of B cell metabolism in autoimmune diseases. Autoimmun Rev 2022;:103116. [PMID: 35595053 DOI: 10.1016/j.autrev.2022.103116] [Reference Citation Analysis]
9 Liang SJ, Zheng QY, Li MS, Lv MY, Chen WT, Yang Y. Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review. Clin Rheumatol 2022. [PMID: 35524885 DOI: 10.1007/s10067-022-06155-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang F, Xu Z, He X, Sun Y, Zhao C, Zhang J, Jiang WH. Increased B Cell-Activating Factor Expression Is Associated with Postoperative Recurrence of Chronic Rhinosinusitis with Nasal Polyps. Mediators of Inflammation 2022;2022:1-11. [DOI: 10.1155/2022/7338692] [Reference Citation Analysis]
11 Mak A, Chan JKY. Endothelial function and endothelial progenitor cells in systemic lupus erythematosus. Nat Rev Rheumatol 2022. [PMID: 35393604 DOI: 10.1038/s41584-022-00770-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Doyon-Laliberté K, Aranguren M, Poudrier J, Roger M. Marginal Zone B-Cell Populations and Their Regulatory Potential in the Context of HIV and Other Chronic Inflammatory Conditions. Int J Mol Sci 2022;23:3372. [PMID: 35328792 DOI: 10.3390/ijms23063372] [Reference Citation Analysis]
13 Takeda A, Hasegawa E, Yawata N, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Kimura K, Sonoda KH. Increased vitreous levels of B cell activation factor (BAFF) and soluble interleukin-6 receptor in patients with macular edema due to uveitis related to Behçet's disease and sarcoidosis. Graefes Arch Clin Exp Ophthalmol 2022. [PMID: 35230474 DOI: 10.1007/s00417-022-05600-1] [Reference Citation Analysis]
14 Lim YL, Bohelay G, Hanakawa S, Musette P, Janela B. Autoimmune Pemphigus: Latest Advances and Emerging Therapies. Front Mol Biosci 2022;8:808536. [DOI: 10.3389/fmolb.2021.808536] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
15 Tanaka Y; The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis. Rheumatology 2022;1:32. [DOI: 10.17925/rmd.2022.1.1.32] [Reference Citation Analysis]
16 van Beers JJ, Schreurs MW. Anti-Sm antibodies in the classification criteria of systemic lupus erythematosus. Journal of Translational Autoimmunity 2022;5:100155. [DOI: 10.1016/j.jtauto.2022.100155] [Reference Citation Analysis]
17 Zhang Y, Tian J, Xiao F, Zheng L, Zhu X, Wu L, Zhao C, Wang S, Rui K, Zou H, Lu L. B cell-activating factor and its targeted therapy in autoimmune diseases. Cytokine & Growth Factor Reviews 2021. [DOI: 10.1016/j.cytogfr.2021.11.004] [Reference Citation Analysis]
18 Raymond WD, Hamdorf M, Furfaro M, Eilertsen GO, Nossent JC. Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus. Lupus Sci Med 2021;8:e000537. [PMID: 34725185 DOI: 10.1136/lupus-2021-000537] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Zhou B, Li S, Ye J, Liu Y, Hu L, Tang Y, Wu Z, Zhang P. Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19. Int Immunopharmacol 2021;101:108254. [PMID: 34710657 DOI: 10.1016/j.intimp.2021.108254] [Reference Citation Analysis]
20 Wang Y, Xiao S, Xia Y, Wang H. The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies. Clin Rev Allergy Immunol 2021. [PMID: 34542806 DOI: 10.1007/s12016-021-08898-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Quartuccio L, De Marchi G, Longhino S, Manfrè V, Rizzo MT, Gandolfo S, Tommasini A, De Vita S, Fox R. Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine. Front Immunol 2021;12:703780. [PMID: 34322134 DOI: 10.3389/fimmu.2021.703780] [Reference Citation Analysis]
22 Fagone P, Mangano K, Di Marco R, Reyes-Castillo Z, Muñoz-Valle JF, Nicoletti F. Altered Expression of TSPAN32 during B Cell Activation and Systemic Lupus Erythematosus. Genes (Basel) 2021;12:931. [PMID: 34207245 DOI: 10.3390/genes12060931] [Reference Citation Analysis]
23 Basta F, Möckel T, Petersohn J, Meineck M, Triantafyllias K, Engel S, Weinmann A, Luessi F, Weinmann-Menke J, Schwarting A. The relationship between BAFF serum levels, anti-NMDAR autoantibodies and fatigue in patients with systemic lupus erythematosus and multiple sclerosis. Autoimmun Rev 2021;20:102802. [PMID: 33727153 DOI: 10.1016/j.autrev.2021.102802] [Cited by in F6Publishing: 4] [Reference Citation Analysis]